Skip to main content

CASE REPORT article

Front. Oncol.
Sec. Breast Cancer
Volume 14 - 2024 | doi: 10.3389/fonc.2024.1419246

Expanding treatment options for patients with HER2+ metastatic breast cancer with margetuximab plus chemotherapy: A Case Report Series

Provisionally accepted
Reshma L. Mahtani Reshma L. Mahtani 1,2,3*Natasha Harpalani Natasha Harpalani 2Fengting Yan Fengting Yan 4,5Kristen Phiel Kristen Phiel 6Iuliia Kovalenko Iuliia Kovalenko 7*
  • 1 Baptist Health South Florida, Miami, Florida, United States
  • 2 Miami Cancer Institute, Baptist Hospital of Miami, Miami, Florida, United States
  • 3 Memorial Sloan Kettering Cancer Alliance - Miami Cancer Institute, Miami, United States
  • 4 Swedish Cancer Institute, Seattle, Washington, United States
  • 5 First Hill - True Family Women's Cancer Center, Seattle, United States
  • 6 Eversana, Amherst, United States
  • 7 UPMC Harrisburg, Harrisburg, United States

The final, formatted version of the article will be published soon.

    HER2+ breast cancer (BC) accounts for approximately 14% of total BC cases in the United States; it is highly aggressive, has a high associated risk for mortality, and a poor prognosis. These case reports demonstrate that margetuximab plus chemotherapy is a valid option for patients with HER2+ metastatic (M) BC who have received multiple HER2-targeted agents. Frontiers in Oncology is the great fit for these reports as it provides information in the setting of HER2+ MBC in which more treatment options are needed for patients.

    Keywords: Margetuximab, HER2+, metastatic breast cancer, later-line treatment, case report

    Received: 17 Apr 2024; Accepted: 24 Jul 2024.

    Copyright: © 2024 Mahtani, Harpalani, Yan, Phiel and Kovalenko. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence:
    Reshma L. Mahtani, Baptist Health South Florida, Miami, Florida, United States
    Iuliia Kovalenko, UPMC Harrisburg, Harrisburg, United States

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.